RxPonder is not a noninferiority study showing that we lose very little by skipping chemotherapy for postmenopausal women with 1 to 3 positive axillary nodes and OncotypeDx recurrence score (RS) (Genomic Health, now bought by Exact Sciences) less than 26. However, it comes close enough to establishing noninferiority for physicians and patients to proceed as if it were so.
RxPonder included 3,350 postmenopausal women who had resected breast cancer